INSIGHTS ON DOWNSTREAM MANUFACTURING

• The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time

  See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

• Performing Virus Clearance Studies With Retroviral-Like Particles: Updated Guidance

  Updated regulatory standards now support using non-infectious retroviral-like particles for viral clearance. This shift reduces costs and accelerates timelines for biomanufacturers.

• A Gentler Workflow: Fc-fusion Protein Purification With Mixed-Mode And Anion Exchange Chromatography

  Gain insights into comparative performance, workflow flexibility, and practical considerations for implementing a new weak anion exchange hydrophobic resin and a strong anion exchange resin.

• WuXiHigh 2.0 Delivers A 180 mg/mL Formula

  This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

• Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing

  3/26/2026

  See how modern tool enzymes enable cleaner, more consistent ADC conjugation, sharper analytics, and a smoother path from research to clinical development — practical guidance for manufacturing.

• Ensure Successful Viral Clearance

  3/26/2026

  A decade of viral clearance data comparing established and emerging operations, highlighting LRV performance, key process risks, and practical insights to strengthen downstream safety.

• AST Origins: Pioneering RTU Flexibility With Robotic Fill-Finish Systems

  3/25/2026

  Modernize sterile manufacturing with robotic fill-finish systems. Achieve multi-format flexibility and risk reduction to meet the rigorous demands of personalized medicine and small-batch production.

• To 10X & Beyond, AgentV™-DSP Arrives Ready To Rock

  3/25/2026

  Filter fouling has limited exosome therapeutic scalability—until now. Explore how a breakthrough reagent achieves 50% particle recovery versus 5% traditionally, enabling affordable clinical manufacturing.

• EV Content vs. Function: Using Analytical Tools To Reveal The Connection

  3/25/2026

  See how downstream processing affects CD73 expression and function on MSC-EVs through orthogonal analytical methods that connect vesicle content to biological activity and therapeutic potential.